Solubility and permeability are intimately linked in drug absorption processes. They have, however, been traditionally assayed separately. To support this linkage, a combined solubility/permeability assay was developed for determining absorption properties of chemical entities. First, solubility is determined at 4 pH values by comparing the concentration of a saturated compound solution to its dilute, known concentration. The filtered, saturated solution from the solubility assay is then used as input material for the membrane permeability determination. The permeability assay is a parallel artificial membrane technique whereby a membrane is created on a solid support parallel artificial membrane permeation assay (PAMPA). The 2 artificial membranes presented here model the gastrointestinal tract and the blood-brain barrier (BBB). Data are presented for control compounds, which are well documented in the literature and exemplify a range of solubility and membrane permeability. The advantages of the combination method are 1) reduction of sample usage and preparation time, 2) elimination of interference from compound precipitation in membrane permeability determination, 3) maximization of input concentration to permeability assay for improved reproducibility, and 4) optimization of sample tracking by streamlining data entry and calculations. BBB permeability ranking of compounds correlates well with literature CNS activity. (Journal of Biomolecular Screening 2005:383-390) Journal of Biomolecular Screening 10(4); 2005 www.sbsonline.org 387 FIG. 2. Blood-brain barrier-parallel artificial membrane permeation assay (BBB = PAMPA) effective permeability (P e ) plotted versus input concentration. Input concentration for the 8 compounds (a-h) were serial diluted 1:2 starting with 350 µM. The error bars are the standard deviations calculated from n = 5 experiments.
W ITH AN EVER INCREASING PRESSURE to push compounds through the drug discovery pipeline, there is a steady demand for reliable, high-throughput assay technologies in bottleneck areas. One bottleneck area that has received significant attention lately is ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicology). The pressure is then compounded by the fact that 40% of late-stage failures are associated with poor pharmacokinetic properties, 1 such as low oral absorption. In the present article, we focus on the 2 major factors of absorption: solubility and membrane permeability. [2] [3] [4] [5] [6] The focus of this report is to develop a high-throughput process that will integrate both solubility and permeability assays to increase throughput and decrease cost.
Several different techniques are available for determining aqueous solubility. [7] [8] [9] [10] [11] [12] After reviewing the available technologies for solubility testing, the direct ultraviolet (UV) method 13 was chosen based on its adaptability into a high-throughput format, low cost, and reliability. One potential problem for the direct UV method is compounds with weak UV absorption; however, these compounds are in the minority. If required, other detection methods such as high-performance liquid chromatography or liquid chromatography/mass spectrometry can be implemented. The direct UV method requires a small amount (~0.25 mg) of compound and can be conducted over a wide range of pH values in the presence of many different excipients including DMSO. Importantly, the resulting filtrate from this technique can be used as a sample for subsequent permeability measurements.
Physicochemical methods for predicting membrane permeability have evolved from simple logP determination [14] [15] [16] [17] to more sophisticated in vitro systems such as the parallel artificial membrane permeation assay (PAMPA) 18 and biological cell layers (i.e., Caco-2). 19, 20 Biological cell layers are able to model most of the transport mechanisms available for drug permeation: passive diffusion (transcellular and paracellular) and active transport (influx and efflux). Because the primary route of drug absorption for a vast majority of compounds is passive transcellular diffusion, the PAMPA technique was chosen to model this specific pathway to predict membrane permeability. PAMPA uses an artificial lipid membrane on a solid filter support to model the barrier that drugs need to cross for permeability studies. One major advantage of PAMPA is the fact that the components of the lipid membrane solution can be varied to model the desired biological mem-brane, 2, 3, 13, [21] [22] [23] [24] [25] that is, the gastrointestinal tract (GIT) and bloodbrain barrier (BBB). The membrane used in the PAMPA method can be exposed to a wide range of pH values to create a pH gradient, which is a good representation of the environment within the GIT. 3 Because of the specific requirement of compound activity in the CNS, data from the BBB-PAMPA model 25 will be used for discussion in this report.
Solubility and membrane permeability have traditionally been assayed separately. Here, we have developed a process in which the solubility and permeability assays are integrated for optimal performance. First, solubility is determined at 4 pH values by comparing the concentration of a saturated compound solution to its dilute, known concentration. The filtered, saturated solution from the solubility assay is then used as input material for the membrane permeability determination. The benefits of this integrated process include reproducibility, sensitivity (maximize input sample concentration), improved process flow, and increased throughput.
MATERIALS AND METHODS

Materials
A 45 mM, constant ionic strength (150 mM), phosphate buffering system at 4 pH values 26 was used in both solubility and permeability assays. The commercial drugs amitriptyline (A-8404), caffeine (C-0750), carbamazepine (C-4024), clonidine (C-7897), diclofenac (D-6899), dextrophan (D-127), desipramine (D-3900), n-dodecane (D-4259), fluvoxamine (F-2802), isoxicam (I-1762), lomafloxacin (L-2906), MK 801 (M-107), phenazopyridine (P-8420), N-tert-butyl-alpha-phenylnitrone (180270), piroxicam (P-0847), s-propranolol (P-8688), N-methylquipazine dimaleate (Q-107), ranitidine (R-101), SKF 95282 (S-5317), SR 57227A (S-1688), theophylline (T-1633), and verapamil (V-4629) were purchased from Sigma Chemical Co. (St. Louis, MO). Compounds AGY-0064873 and AGY-0094806 were from AGY Therapeutics' proprietary in-house library. DMSO was reagent grade from Burdick & Jackson (Muskege, MI). The porcine brain polar lipid (141101P) was purchased from Avanti Polar Lipids (Alabaster, AL), and the egg lecithin (P-3556) was purchased from Sigma Chemical Co. (St. Louis, MO). The dodecane was minimum 99% by GC from TCI America (Portland, OR). The MultiProbeII HT liquid handling system was purchased from Perkin Elmer Life Sciences (Boston, MA). The 96-deepwell plates (267006), the 96-tip Biomek FX liquid handling system, and the Biomek 2000 liquid handling system were supplied by Beckman Coulter (Fullerton, CA). The MultiScreen-Solubility 96-well filter plates (MSSLBPC10), the PTFE donor plate (MSSACCEPTOR), and the MultiScreen-IP 96-well filter plates (MAIPN4510) were acquired from Millipore (Danvers, MA). The 384-well UV/Vis plates (3675) were purchased from Corning (Corning, NY). The SpectraMaxPlus384 microplate reader and SoftMaxPro ® software were obtained from Molecular Devices (Sunnyvale, CA).
Solubility
The method of solubility determination described here is a modified version of the direct UV method described previously. 13 The automation and specific assay parameters are included here to highlight the details and improvements to the method. A MultiProbeII HT liquid handling system was used to set up the solubility experiments. The 35-mM compound stock solutions in DMSO were transferred from 1.5-mL centrifuge tubes into 96deepwell plates containing aqueous buffer solutions of 4 different pH values (3, 5, 7.4, 9) . The final volume and concentration of the sample and reference solutions were 500 µL at 350 µM and 200 µL at 35 µM, respectively, both with 1% DMSO content. To ensure complete solubility of the compound in the reference wells, methanol was added as a cosolvent at 20% v/v. The aqueous and aqueous/methanol solutions were shaken for 90 min at room temperature. Using a 96-tip Biomek FX liquid handling system, the solutions were transferred to a MultiScreen-Solubility 96-well filter plate, vacuum filtered, and collected into a clean 96-deepwell plate. 75 µL of the reference filtrate, and 60 µL of the sample filtrate, was then pipetted using the 96-tip Biomek FX to a 384-well UV/Vis plate for analysis. The sample solutions were diluted in the UV/Vis plate with predispensed methanol (20% v/v) for spectroscopic consistency between sample and reference. The remaining portion of the filtrate was sealed and kept in a cool, dark place for 1 to 2 h before set up of the permeability assay. The UV spectrum of each well was measured using a SpectraMaxPlus384 microplate reader between 250 and 550 nm at 5-nm intervals. The absorption spectra were then corrected for variance in path length by the PathCheck™ 27 algorithm in the SoftMaxPro ® software. Next, the optical density (OD) at an appropriate wavelength (λ) was determined for each compound by an in-house analysis algorithm. a The concentrations of the compounds in solution were then determined by the following formula:
where OD(λ) Sample and OD(λ) Reference are the optical densities at a given wavelength for each compound, Reference [µM] is the same compound at a known reference concentration, and the 0. a. The ultraviolet (UV) visible spectra were analyzed by an in-house program written in HPBASIC for Windows (TransEra Corporation, Orem, UT). Briefly, from the spectrum of each well, a heuristically matched, scaled, and appropriately shifted baseline was subtracted. The locations (λ) and the values of all the peaks [OD(λ)] were then determined. Optical density (OD) values larger than 4 and smaller than 0.05 were ignored. The program correctly identified the best OD values in most cases. In addition, built-in user interface tools offered a convenient way to review and manually reassign the λ values to address special cases. When no peaks were found in the spectra, the OD values at 265 nM were used. Subsequently, for the solubility calculation, a consensus λ was determined for the sample, and reference spectra and the corresponding OD values were used in equation (1) . For the P e calculation, a consensus λ value was determined for the donor-, acceptor-, and mass balance-wells, and the corresponding OD values were used in equations (2a) and (2b).
For the solubility portion of the screen, the compounds are quantitatively assessed in the range of 0 to 350 µM. A compound is determined to have a solubility of <35 µM, if that compound is completely soluble in the co-solvent mixture (80% buffer, 20% methanol) but not soluble in 100% buffer. However, if the true compound solubility is greater than 350 µM, it is assigned a value of >350. Setting the sample concentration to 350 µM (corresponding to~100 mg/L w/v concentration based on the average molecular weight of 350 of the compounds in our library) affords the determination of the solubility values in the range of >10 mg/L amenable for drug candidates.
Permeability
The PAMPA method for permeability determination employed here is similar to that described previously 18, 25 ; the automation and specific assay details are included here to demonstrate the improvement in the methods. Using a Biomek 2000 liquid handling system, 290 µL of the solubility filtrate was transferred to the PTFE donor plate. The membrane solutions were then created by dissolving 20 mg/mL of the appropriate phospholipid in dodecane. The egg lecithin solution at this concentration required sonication for 1 to 2 min for complete dissolution. Using a 96-tip Biomek FX, the filter membrane in the wells of the MultiScreen-IP filter plate was coated with 5 µL of membrane solutions and, within 2 min, the wells were filled with 150 µL of pH 7.4 buffer. Egg lecithin and porcine brain polar lipid were used for the GIT and BBB membranes, respectively. The filter acceptor plate was then carefully placed on top of the PTFE donor plate to initiate the permeation process. The plate complex was allowed to incubate for 16 h at room temperature in a humidity-controlled environment. The acceptor plate was carefully removed, and then 75 µL from the acceptor plate, donor plate, and solubility filtrate plate was transferred to a 384-well UV/Vis plate for analysis. The solution directly from the solubility filtrate plate was used to establish the mass balance in the determination of the percentage membrane retention calculation. The ODs of each sample were determined by the same methods and corrections as that mentioned in the solubility section above. The effective permeability (P e ) of each compound was calculated using the following equations 2, 3, 23 :
) of the donor well, V A is the volume (cm 3 ) of the acceptor well, V mem is the volume (cm 3 ) in the membrane, area is the effective area (0.24 cm 2 ) of the membrane, time is the incubation time (seconds), [drug] A is the concentration of drug (moles/ cm 3 ) that permeated into the acceptor well, and [drug] Eq is the con-centration of the drug (moles/cm 3 ) in the system as if no membrane were present.
[drug] Eq is determined using the ODs of the mass balance wells, which are solutions taken directly from the initial solubility filtrate plate.
Extinction coefficient
Compounds were solubilized in pH 7.4 phosphate buffer at 4 concentrations (175, 88, 44, and 22 µM) and then 75 µL was transferred to 384-well UV plates. UV spectra were measured from 250 to 550 nm. The appropriate wavelength (λ) was selected for each compound, and then the OD value was used as input to Beer's law equation, A = ε(λ) • c • l, where A is absorbance (OD), c is concentration (moles/cm 3 ), and l is the path length (cm). The path length for each well was determined using the PathCheck™ 27 algorithm in the SoftMaxPro ® software. Extinction coefficients at compound specific wavelengths, ε(λ), were then determined for each com- The average coefficient of variation for each of the solubility values was 11% (n = 5).
pound. The average ε from the 4 concentrations are reported in Table 1 .
RESULTS AND DISCUSSION
The purpose of integrating the solubility and permeability assays was to improve laboratory efficiency, reduce potential sources of systematic error, and maximize sensitivity in the detection method. To demonstrate the benefits of this process flow, 8 control compounds were used. First, the solubility of these compounds was measured and compared to the data from the literature. Second, effective permeability data are compared for the 8 control compounds assayed at 2 concentrations, at the solubility limit of each compound and at a fixed concentration. Assaying compounds for permeability at their solubility limit offers the following advantages: 1) no possibility of precipitate interfering with the membrane and membrane permeability determination [for the cases of precipitation, different calculation methods other than those presented in equations (2a) and (2b) may apply 3 ], 2) the exact amount of compound in the system is known, and 3) improved sensitivity and reproducibility due to assaying at the highest possible concentration of each compound. Finally, a larger set of compounds is used to create a compound-ranking system for CNS activity, and the new ranking system is compared to both in vitro and in vivo literature data.
Solubility
To test and validate the new solubility-permeability combination method, the following 8 control compounds were selected: caffeine, desipramine, diclofenac, phenazopyridine, piroxicam, propranolol, theophylline, and verapamil. These specific compounds were chosen because they are well-characterized drugs in ADME literature, they exemplify a range of P e values, and they represent some of the diversity that might be encountered in a drug discovery environment. Table 1 shows the solubility values that were determined along with the extinction coefficient (ε) at the relevant wavelength (λ). In general, the data are in good agreement with the published data generated using similar solubility methods. 3, 28 The pH-dependent solubility is demonstrated nicely with compounds such as diclofenac, phenazopyridine, piroxicam, and verapamil. The solubility for diclofenac, a weak acid, increases with pH. The opposite trend is observed for the weak base phenazopyridine. Determining the solubility for a range of gastrointestinal-relevant pH values provides valuable data as to the total compound potentially available for absorption at the various locations in the gut. 
Permeability
To demonstrate the benefit of assaying compounds at their solubility limit, the effective permeability (P e ) was measured for the 8 control compounds in BBB-PAMPA at 2 initial (t = 0) donor well concentrations. For each compound, 1 input solution was an aliquot of the filtrate from the solubility assay and the other input solution was fixed at 100 µM. A fixed initial donor well concentration is general practice in most laboratories. Figure 1 shows the average P e for 5 experiments plotted with standard deviations as error bars. The P e values obtained from the 2 different input concentrations agree within experimental error. More important, a significant reduction in the standard deviation of the average P e is observed when compounds are assayed at their solubility limit versus at a fixed concentration of 100 µM. To fur-ther quantitate the reduction in error, the coefficients of variation (%CV = standard deviation/average × 100) are given as numbers for each condition in Figure 1 . For each compound, there is a significant decrease in %CV when assaying at the solubility limit versus at 100 µM. By testing compounds at their solubility limit, we maximize the amount of compound in solution and therefore improve analytical sensitivity.
According to Beer's law, the measured OD for each compound is dependent on the molar extinction coefficient (ε), concentration ([drug]), and path length (l). Therefore, by assaying at the highest concentration possible (solubility limit), the reproducibility is improved and the probability of measuring a signal for every compound is increased. The number of low soluble compounds is increasing, and this technique would therefore benefit a larger number of compounds in drug discovery pipelines.
Another benefit of assaying compounds at their solubility limit is the elimination of drug precipitation in the donor compartment. When precipitation occurs in the donor well, a saturated solution is established for the entire permeation experiment and therefore requires a different formula for calculation of P e . 3 By eliminating the possibility of precipitation, the use of equations (2a) and (2b) is ensured for all samples.
Because compound-to-compound solubility does vary, it is important to demonstrate that the P e value measured at the solubility limit of each compound represents the true permeability of that compound. Figure 2 is a graph of P e versus input concentration measured using BBB-PAMPA for the 8 control compounds. The majority of the compounds (Figs. 2a-2e) show no dependence of P e on concentration, within experimental error, in accordance with 1st-order rate kinetics.
Theoretically, passive diffusion follows 1st-order rate kinetics, the initial rate constant of which, that is, permeability, should not be dependent on compound input concentration. The observed dependence of P e on input concentration for a few compounds can be explained by compound detection limitations. At low input compound concentration, the experimental error becomes larger as a result of low absorbance values approaching the detection limit of the instrument. The reduction in detectable compound can be assigned to either low molar absorbance coefficient ε (propranonol, Fig. 2f ) or low P e (theophylline, Fig. 2g ). Diclofenac (Fig. 2h) is a highly permeable molecule (P e ≈ 10 × 10 -6 cm/s), and the observed P e shows a slight (less than 2-fold) but significant increase. This observed concentration dependence could be due to complications from effects such as the unstirred water layer 3, 23, 29, 30 or long permeation times (16 h). Despite the deviation from the initial rate kinetics, this slight increase in P e would not change our permeability ranking of these compounds.
Throughput and analytical sensitivity
To maintain the demanding throughput required in today's drug discovery laboratories, a majority of the steps in the integrated solubility-permeability assay (Sol-PAMPA) have been automated.
With minimal instrumentation and personnel (1 MultiProbe, 1
Biomek FX96, 1 SpectraMaxPlus, and 1 full-time employee), the throughput for the solubility and permeability portions of the assay are 224 data points per day and 168 data points per 2 days, respectively. These numbers correlate to a full solubility and permeability profile of 56 compounds in 2 days. This throughput could be increased on demand by adding other liquid handling stations. The solubility plate format consists of 7 compounds being tested in duplicate at 4 pH conditions. The PAMPA plate format consists of 14 compounds being tested in the GIT model (2 pH conditions: 5 to 7.4 and 7.4 to 7.4) and in the BBB model (1 pH condition: 7.4 to 7.4). By including both permeation model membranes on a single PAMPA plate, compound handling (e.g., freeze thaw cycles) is further minimized.
The throughput of Sol-PAMPA has been increased compared to separate solubility and PAMPA assays due to the following reasons. First, sample preparation from DMSO stock solutions for the permeability portion of the assay has been eliminated. By using the filtrate of the solubility assay as input to PAMPA, the redundancy of creating similar aqueous solutions for each of the 2 individual assays is removed. The liquid handling steps involved in sample preparation, either by human or by robot, can be time-consuming and require large dead volumes of precious compound. By having only 1 of these steps in the process, time and compound usage (250 µg for a complete experiment) are minimized.
Second, data analysis is streamlined by combining the process for both solubility and permeability into 1 analysis template. A substantial amount of time is required to enter compound information prior to analysis and upload for both the solubility and permeability assays. Therefore, by performing the calculations and data transfer in 1 template, redundancy is eliminated in the data entry of the same information.
Third, because 384-well plates are used for UV/Vis spectral analysis, four 96-well plates can be combined into a single analysis plate. For solubility, 28 compounds (7 compounds × 4 plates) at 4 pH values are now analyzed in a single UV plate. For PAMPA, all of the necessary assay components (acceptor, donor, mass balance, and blanks) can now be read on a single plate for internal consistency and help to minimize plate-to-plate variability. Importantly, 96-and 384-well UV plates are expensive (~$10), and a substantial cost savings has been realized by using 384-well plates, thus reducing plate consumption. Overall, the above system improvements reduce plate reading time, minimize plate handling and tracking problems, increase assay sensitivity, and decrease cost.
Another benefit of using a 384-versus a 96-well UV plate is the increase in path length and hence higher OD when measuring equal sample volumes. The geometry of most plate readers used in absorption measurement is such that the light path through the sample is from the bottom of the well to the detector above the well. Therefore, the height of the solution in the well dictates the path length. For a typical well in a 384-well plate, the path length through the solution is almost 3 times longer than for the same volume in a 96-well plate (0.66 cm vs. 0.23 cm for a 75-µL sample).
Because absorbance is directly proportional to path length, the sensitivity is greatly improved by analyzing a set volume in the 384-well plate geometry.
Comparison with in vivo data
The Sol-PAMPA method is set up to qualitatively rank compounds for bioavailability and CNS permeability. Here, we focus on the CNS predictability of the PAMPA-BBB model. In maintaining that focus, a set of 18 compounds with known in vivo CNS activity ranking was assembled as a test set for the combined method. This set of compounds is made up of some well-known drug compounds as well as some that have been run in our laboratories (i.e., AGY-0064873 and AGY-0094806). Table 2 shows solubility, BBB-PAMPA P e , AGY ranking, and comparative CNS activity from the literature. One column contains a compound classification scheme for the PAMPA-BBB to predict BBB permeation that was established by Di et al., 25 in which compounds with P e > 4.0 × 10 -06 are classified as CNS+ and P e < 4.0 × 10 -06 as CNS-. The ranking scheme employed in this report has been adjusted empirically to fit the experimental P e data generated by this test set of compounds and then correlated to previously reported PAMPA-BBB and in vivo BBB permeation data. In the Sol-PAMPA method, CNS+ compounds have a P e > 2.0 × 10 -06 cm/s and CNS-compounds have a P e < 2.0 × 10 -06 cm/s. Be- cause of laboratory-to-laboratory variability, it is recommended (see Di et al. 25 ) that the classification scheme be modified for each laboratory operation. In the test set presented here, caffeine is the only outlier. Caffeine is known to enter the brain by both passive diffusion and carrier-mediated transport, 31 and therefore PAMPA-BBB will underestimate the in vivo BBB permeability. With the slightly adjusted ranking scheme, the P e data in this report are in good agreement with the literature PAMPA-BBB ranking and in vivo CNS permeability (determined by in-house in vivo experiments). 32 In Table 2 , a column containing quantitative in vivo literature information for 8 of the compounds is included for comparison. These numerical data are derived from a rat model that quantitates the ratio of concentrations of drug that permeates into the brain compared to that which remains in the blood. 32 The correlation between the [Blood]/[Brain] numerical data and the P e values generated by Sol-PAMPA BBB model is poor. A linear fit to the data was attempted (data not shown), and an R 2 of 0.49 was achieved. This could be the result of many different factors, such as the different plasma-protein-binding ability of each compound. However, the ranking as CNS+ or CNS-of these compounds does give an accurate representation of this quantitative information.
The purpose of this report was to demonstrate the utility of an in vitro compound ranking system based on GIT-and BBB-PAMPA models. Equations (2a) and (2b) are sufficient for determining P e to rank compounds for GIT and BBB activity. For more quantitative studies of permeability, the ability of a drug to traverse the unstirred water layer (UWL) must be taken into account. Detailed discussions of how to address the UWL in artificial membrane model systems have been reported in the literature. 3, 23, 29, 30 SUMMARY Solubility and permeability are 2 critical parameters in the drug absorption process. As a natural extension of this principle, we have integrated the 2 assays to form the Sol-PAMPA process flow. The advantages of the combination method are 1) reduction of sample usage and preparation time, 2) elimination of interference from compound precipitation in membrane permeability determination, 3) maximization of input concentration (solubility limit of each compound) to permeability assay for improved reproducibility, and 4) optimization of sample tracking by streamlining data entry and calculations. The data generated from Sol-PAMPA are in good agreement with current literature, and BBB permeability ranking of compounds correlates well with literature CNS permeability.
